Contract analysis

I. Opening Statement Talking Points

I.A. Introduction and Framing Mr. Cross should open the conference by thanking Appeals Officer Castañeda for scheduling the conference and for her attention to the matter. The introduction should be warm, professional, and efficient. The following script provides a framework, though Mr. Cross should deliver the remarks conversationally. Suggested Language: "Good morning, Ms. Castañeda. Thank you for scheduling this c

I.B. Summary of PPC's Position After the introductory framing, Mr. Cross should provide a concise overview of PPC's affirmative position. This summary is designed to orient the Appeals Officer before the detailed discussion of each issue. Suggested Language: PPC's position rests on four principal pillars: First, PPC's intercompany arrangements — specifically, the qualified cost-sharing arrangement ("CSA") with Penter

I.C. Summary of the IRS Proposed Adjustment Mr. Cross should briefly summarize the proposed adjustments so that all parties are working from the same baseline. This also demonstrates command of the record and invites the Appeals Officer to follow along. Suggested Language: "For the record, let me briefly summarize the proposed adjustments as set forth in the NOPA dated October 12, 2023." The proposed adjustments are

II. Issue 1: Cost-Sharing Arrangement — Reasonably Anticipated Benefits and Cost-Sharing Ratios

II.A. Background and Key Facts This is the largest of the proposed adjustments at $235.01 million, and the area of greatest quantitative contention between PPC and the examination team. Mr. Cross should lay the factual foundation carefully. Key Facts to Establish: The CSA was executed effective July 1, 2012, between PPC, as the U.S.-based participant, and PBI, as the non-U.S. participant. The CSA is a qualified cost-

II.B. IRS Position (to Rebut) The examination team's NOPA proposes increasing PBI's cost-sharing percentage by 8 to 12 percentage points across the four examination years, as follows: The examination team's primary theory is that PPC's revenue projections for purposes of determining reasonably anticipated benefits understated the value attributable to U.S.-source activities. In essence, the IRS contends that a greate

II.C. PPC's Affirmative Talking Points Mr. Cross should present the following affirmative points in support of PPC's cost-sharing ratios. These talking points establish that the ratios were properly determined under the applicable regulations and are corroborated by reliable economic analysis. Point 1: Methodology Complies with the Regulations. PPC's cost-sharing ratios were determined using the methodology prescribe

II.D. Rebuttal of PCT Undervaluation Claim The IRS's secondary argument — that the $312 million PCT payment undervalued the pre-existing IP portfolio — requires direct rebuttal, even though it relates to a transaction that occurred in 2012, outside the examination years. Point 1: The IRS's WACC Is Inappropriately Low. The IRS's $852 million PCT valuation relies on Dr. Alan Washburne's income method / Discounted cash

II.E. Anticipated Questions and Responses The following questions may arise during the conference regarding the CSA cost-sharing ratio issue. Mr. Cross should be prepared to respond substantively but concisely. Q: Why did PBI's cost-sharing percentage increase over the period? A: The cost-sharing percentages increased from 38.2% to 42.7% because non-Americas revenue grew as a proportion of global revenue during this

III. Issue 2: Legacy IP Royalty Rate (4.5% vs. IRS's 11.0%)

III.A. Background and Key Facts In addition to the CSA governing the jointly developed IP portfolio, PBI licenses certain legacy compounds from PPC. These are compounds that pre-date the formation of the CSA in 2012 and are not covered by the cost-sharing arrangement. PBI pays PPC a royalty of 4.5% of net sales of these legacy compounds in the non-Americas territory. The legacy compound portfolio consists of mature p

III.B. IRS Position (to Rebut) The examination team proposes increasing the royalty rate from 4.5% to 11.0%, asserting that PPC's legacy IP commands a higher royalty based on the IRS economist's analysis of third-party pharmaceutical licensing agreements using the comparable uncontrolled transaction ("CUT") method. The proposed additional royalty adjustments are as follows: The 11.0% royalty rate proposed by the IRS

III.C. PPC's Affirmative Talking Points Point 1: PPC Applied the CUT Method — the Best Method for Royalty Rate Testing. PPC applied the comparable uncontrolled transaction method under Treasury Regulation Section 1.482-4, which is the most direct and reliable method for testing intercompany royalty rates when comparable third-party license agreements are available. The CUT method directly compares the royalty rate ch

III.D. Anticipated Questions and Responses Q: Why did PPC use a 4.5% rate rather than the median 4.4%? A: The 4.5% royalty rate was established at the time the legacy license was negotiated, prior to 2012, based on contemporaneous benchmarking against available comparable agreements. It is within the interquartile range and essentially at the median. The 0.1 percentage point difference between 4.5% and the 4.4% media

IV. Issue 3: Economic Substance of PBI

IV.A. Background and Key Facts The IRS's NOPA asserted, in part, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. The examination team argued that key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — remained concentrated in the United States, and that PBI was essentially a holding company or conduit entity without the functional

IV.B. PPC's Affirmative Talking Points — PBI Substance Evidence Mr. Cross should present the following evidence systematically, covering personnel, governance, physical presence, regulatory activity, commercial decision-making, risk bearing, financial infrastructure, manufacturing oversight, and financial scale. Personnel: PBI grew from 52 employees at the time of incorporation in 2012 to 185 employees by the end of

IV.C. DEMPE Analysis Framework To organize the economic substance evidence within the analytical framework that the Appeals Officer will apply, Mr. Cross should walk through each DEMPE function and demonstrate PBI's substantive contributions. The following analysis corresponds to the DEMPE Functions Matrix that has been prepared as an exhibit. Development: PBI co-funded R&D costs under the CSA, bearing 38.2% to 42.7%

IV.D. Legal Authority The legal standard for economic substance in the transfer pricing context is well established and supports PBI's position. Under Treasury Regulation Section 1.482-7, a controlled participant in a qualified cost-sharing arrangement must exercise control over the development and exploitation of the covered intangibles. PBI clearly satisfies this requirement through its co-funding of R&D, its manag

IV.E. Anticipated Questions and Responses Q: How much of PPC's total R&D activity was performed in the U.S. versus Ireland? A: The majority of laboratory research and early-stage clinical development was performed in the United States at PPC's research facilities. However, PBI managed non-Americas regulatory submissions, late-stage clinical trial coordination for non-Americas jurisdictions, and commercial development

V. Issue 4: PCT Valuation (Indirect — Supporting CSA Arguments)

V.A. Core Talking Points Although the PCT payment was made on July 1, 2012, and falls outside the examination years of 2017 through 2020, the IRS has invoked the PCT valuation as a supporting basis for its proposed adjustments to the ongoing CSA cost-sharing ratios. Accordingly, PPC must address the PCT valuation to prevent it from being used as a lever to increase the proposed CSA adjustments. Point 1: The PCT Payme

V.B. Anticipated Questions and Responses Q: Why should we accept a 9.8% WACC over 7.2%? A: The 9.8% WACC is derived from a rigorous cost-of-capital analysis using pharmaceutical-industry betas with adjustments for PBI's specific risk profile, including regulatory approval risk for clinical-stage compounds, geographic market-entry risk in territories where PBI had not yet established operations, and pipeline attrition

VI. Issue 5: Correlative Offset

VI.A. Talking Points PPC acknowledges that the examination team has allowed a correlative offset of $42.65 million in computing the net proposed adjustment. This offset is intended to avoid double-counting between the CSA cost-sharing adjustments and the royalty adjustments, recognizing that an increase in cost-sharing payments by PBI and an increase in the royalty rate paid by PBI are not fully independent — they ov

VII. Issue 6: IRC § 6662(e) Penalty — Reasonable Cause Defense

VII.A. Background The IRS proposed the substantial valuation misstatement penalty under IRC Section 6662(e) in connection with the Section 482 adjustments. The penalty is computed at 20% of the underpayment of tax attributable to the substantial valuation misstatement. As computed in the NOPA: The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC Section 6662(h), which would apply

VII.B. PPC's Affirmative Defense Talking Points PPC has a strong and well-documented reasonable cause defense against the proposed penalty. PPC maintained contemporaneous transfer pricing documentation for all four tax years and engaged qualified experts to prepare and validate its transfer pricing positions. The penalty should be fully abated. Point 1: Contemporaneous Transfer Pricing Documentation Satisfies Penalty

VII.C. Anticipated Questions and Responses Q: Does the contemporaneous documentation address all issues raised in the NOPA? A: Yes. The Crestfield-prepared documentation covers the CSA methodology, cost-sharing ratio calculations, PCT valuation, and the CUT analysis supporting the 4.5% royalty rate for each of the four tax years. Every issue raised in the NOPA was addressed in the contemporaneous documentation. Q: Wh

VIII. Settlement Posture and Proposed Resolution Framework

VIII.A. Hazards of Litigation — Summary for Appeals Officer The IRS Appeals function operates within a "hazards of litigation" framework, and the Appeals Officer will evaluate both sides' positions against the risk of an adverse outcome if the case were to proceed to the United States Tax Court. Mr. Cross should frame PPC's settlement discussion accordingly, conveying to Appeals Officer Castañeda that PPC recognizes